- Home
- NMM vs NRIX Comparison
NMM vs NRIX Comparison
Compare NMM & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMM
- NRIX
- Stock Information
- Founded
- NMM 2007
- NRIX 2009
- Country
- NMM Monaco
- NRIX United States
- Employees
- NMM N/A
- NRIX N/A
- Industry
- NMM Marine Transportation
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- NMM Consumer Discretionary
- NRIX Health Care
- Exchange
- NMM Nasdaq
- NRIX Nasdaq
- Market Cap
- NMM 1.4B
- NRIX 1.3B
- IPO Year
- NMM 2007
- NRIX 2020
- Fundamental
- Price
- NMM $42.64
- NRIX $19.83
- Analyst Decision
- NMM Strong Buy
- NRIX Strong Buy
- Analyst Count
- NMM 1
- NRIX 17
- Target Price
- NMM $80.00
- NRIX $30.29
- AVG Volume (30 Days)
- NMM 175.5K
- NRIX 988.4K
- Earning Date
- NMM 02-11-2025
- NRIX 02-13-2025
- Dividend Yield
- NMM 0.47%
- NRIX N/A
- EPS Growth
- NMM N/A
- NRIX N/A
- EPS
- NMM 13.27
- NRIX N/A
- Revenue
- NMM $1,328,798,000.00
- NRIX $56,424,000.00
- Revenue This Year
- NMM N/A
- NRIX N/A
- Revenue Next Year
- NMM $15.76
- NRIX $5.92
- P/E Ratio
- NMM $3.21
- NRIX N/A
- Revenue Growth
- NMM N/A
- NRIX N/A
- 52 Week Low
- NMM $27.47
- NRIX $7.65
- 52 Week High
- NMM $65.89
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- NMM 25.14
- NRIX 38.42
- Support Level
- NMM $42.02
- NRIX $19.38
- Resistance Level
- NMM $44.55
- NRIX $21.67
- Average True Range (ATR)
- NMM 1.41
- NRIX 1.34
- MACD
- NMM -0.24
- NRIX 0.00
- Stochastic Oscillator
- NMM 8.19
- NRIX 12.61
About NMM Navios Maritime Partners LP Common Units Representing Limited Partner Interests
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through chartering of vessels, voyage contracts. Geographically, it generates majority revenue from Asia.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.